Short answer
Merck & Co. (MRK) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.11 (Exhibit EX-99.11). Paul J. Diaz elected to Merck’s Board effective November 1, 2026.
Merck & Co. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Paul J. Diaz elected to Merck’s Board effective November 1, 2026
- Diaz joins Audit Committee, strengthening board oversight of financial reporting and controls
- Diaz also joins Research Committee, adding board-level input on R&D strategy
- Standard non-employee director compensation, with no disclosed related-party arrangements or conflicts
Item EX-99.11 · Exhibit EX-99.11
- Paul J. Diaz joins Merck’s board effective November 1, 2026
- Board expands to 14 members, subject to shareholder election in May 2027
- Healthcare operating and investment experience adds strategic expertise in genetics, healthcare services and managed care
- No immediate changes to Merck’s management, strategy or financial outlook disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Merck & Co. 8-K filings
Get the next MRK 8-K as it lands
Follow MRK for push alerts, or ask the research agent what this filing means.